Literature DB >> 12870169

Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome.

C J Glueck1, Ranganath Papanna, Ping Wang, Naila Goldenberg, Luann Sieve-Smith.   

Abstract

In 138 oligo-amenorrheic white women with polycystic ovary syndrome (PCOS) (31+/-9-years-old), our first specific aim was to assess the incidence of the metabolic syndrome and to compare metabolic syndrome abnormalities in women with PCOS to those in the National Health and Nutrition Examination Survey (NHANES) III cohort of 1,887 white women. Our second aim was to determine whether metformin (2.55 g/d) and a diet of 1,500 calories, 26% protein, 44% carbohydrate (42% of carbohydrate complex), 30% fat (polyunsaturate/saturate ratio [P/S]=2/1), would ameliorate metabolic syndrome abnormalities in women with both PCOS and metabolic syndrome. The metabolic syndrome was present in 64 (46%) of the women with PCOS. In these 64 women, there were abnormalities in waist circumference (98%), high-density lipoprotein cholesterol (HDL-C) (95%), blood pressure (70%), triglycerides (56%), and glucose (11%). In these 64 women, mean +/- SD waist circumference was 116+/-15 cm, triglyceride 192+/-152 mg/dL, HDL-C 39+/-7 mg/dL, systolic blood pressure 131+/-13 mm Hg, diastolic blood pressure 83+/-7 mm Hg, and serum glucose 94+/-22 mg/dL. Serum insulin was high (>17 microU/mL) in 42 of the 64 women (66%). After age adjustment, 46.4%+/-4.2% of women with PCOS had the metabolic syndrome (> or =3 abnormalities) versus 22.8%+/-1.1% of NHANES III women, P<.0001 versus 6% of 20 to 29-year-old and 15% of 30 to 39-year-old NHANES III women. Of the 64 women with both PCOS and the metabolic syndrome, 50 had follow-up studies after an average of 6 months on metformin and diet. At 6 months follow-up, mean percent reductions were as follows: body weight 4.7% (111 to 106 kg, P<.0001), triglycerides 14% (197 to 136 mg/dL, P=.0001), systolic blood pressure 5.2% (131 to 124 mm Hg, P=.0002), diastolic blood pressure 6% (83 to 77 mm Hg, P=.0007), and insulin 31% (25 to 17 microU/mL, P<.0001); mean percent HDL-C increased 6% (39 to 41 mg/dL, P=.013). Of these 50 women, 29 had pretreatment baseline abnormal triglycerides (> or =150 mg/dL), 47 had low HDL-C (<50 mg/dL), 26 had high systolic blood pressure (> or =130 mm Hg), 16 had high diastolic blood pressure (> or =85 mm Hg), and 5 had glucose > or = 110 mg/dL. On metformin plus diet at 6 months, triglycerides moved within guidelines in 10 of 29 (34%) women, HDL-C in 6 of 47 (13%), systolic blood pressure in 16 of 26 (62%), diastolic blood pressure in 10 of 16 (63%), and glucose in 3 of 5 (60%). Metformin and diet ameliorate many of the features of the metabolic syndrome, present in 46% of women with PCOS in the current study, and should reduce risk for atherothrombosis and type 2 diabetes mellitus (DM) in PCOS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12870169     DOI: 10.1016/s0026-0495(03)00104-5

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  67 in total

1.  Age at Onset of Metabolic Syndrome Among Women With and Without Polycystic Ovary Syndrome-Like Status.

Authors:  Qing Peng; Carrie A Karvonen-Gutierrez; John F Randolph; Bin Nan; Daniel McConnell; Siobán D Harlow
Journal:  J Clin Endocrinol Metab       Date:  2019-05-01       Impact factor: 5.958

Review 2.  [Polycystic ovary syndrome. Prototype of a cardio-metabolic syndrome].

Authors:  D Heutling; H Schulz; H Randeva; C Dodt; H Lehnert
Journal:  Internist (Berl)       Date:  2007-02       Impact factor: 0.743

Review 3.  Surgical treatment of obesity.

Authors:  Nancy Puzziferri; Jeanne Blankenship; Bruce M Wolfe
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

4.  Associations between vitamin D levels and polycystic ovary syndrome phenotypes.

Authors:  Erin M Davis; Jennifer D Peck; Karl R Hansen; Barbara R Neas; LaTasha B Craig
Journal:  Minerva Endocrinol       Date:  2018-04-12       Impact factor: 2.184

Review 5.  The metabolic syndrome in polycystic ovary syndrome.

Authors:  P A Essah; J E Nestler
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

Review 6.  Targets to treat metabolic syndrome in polycystic ovary syndrome.

Authors:  Shruthi Mahalingaiah; Evanthia Diamanti-Kandarakis
Journal:  Expert Opin Ther Targets       Date:  2015-10-21       Impact factor: 6.902

Review 7.  Polycystic ovary syndrome in adolescence.

Authors:  Colleen Buggs; Robert L Rosenfield
Journal:  Endocrinol Metab Clin North Am       Date:  2005-09       Impact factor: 4.741

8.  Low sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal women.

Authors:  Melissa E Weinberg; JoAnn E Manson; Julie E Buring; Nancy R Cook; Ellen W Seely; Paul M Ridker; Kathryn M Rexrode
Journal:  Metabolism       Date:  2006-11       Impact factor: 8.694

9.  Gonadal dysfunction in morbidly obese adolescent girls.

Authors:  Vivian Chin; Marisa Censani; Shulamit Lerner; Rushika Conroy; Sharon Oberfield; Donald McMahon; Jeffrey Zitsman; Ilene Fennoy
Journal:  Fertil Steril       Date:  2014-02-26       Impact factor: 7.329

10.  Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome.

Authors:  P A Essah; J E Nestler; E Carmina
Journal:  J Endocrinol Invest       Date:  2008-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.